<unk>  is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA). MRSA infections have become problematic in the community and in healthcare settings due to resistance to many available antibiotics. Because<unk>  has demonstrated efficacy against MRSA and other microorganisms to treat serious or life-threatening infections, it was the first drug approved as a Qualified Infectious Disease Product under the Generating Antibiotic Incentives Now (GAIN) act, which is part of the FDA Safety and Innovation Act. It has strong activity against many Gram-positive bacteria, including methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus. Based on MIC data and other studies,<unk>  is more potent and bactericidal and therefore requires lower concentrations than vancomycin against these organisms.<unk>  also shows in vitro activity against vancomycin-susceptible Enterococcus faecium and Enterococcus faecalis. Other Gram-positive organisms belonging to the Bacillus spp., Listeria spp., and Corynebacterium spp. may show in vitro susceptibility, and<unk>  may exhibit activity against enterococci expressing the VanB or VanC phenotype of acquired resistance against vancomycin. There is no clinically significant activity against Gram-negative bacteria. Two trials, DISCOVER 1 and DISCOVER 2, demonstrated noninferiority of<unk>  compared to vancomycin/linezolid in the treatment of ABSSSI. Patients were randomly assigned to receive two doses of<unk>  on days 1 and 8, or to receive intravenous vancomycin for at least 3 days with the option of switching to oral linezolid to complete 10 to 14 days of therapy. Investigators assessed the cessation of spread of infection-related erythema and the absence of fever at 48 to 72 hours as the primary endpoint and found that once-weekly<unk>  was as effective as twice-daily intravenous vancomycin followed by oral linezolid. This once-weekly dosing regimen may offer an advantageous treatment option compared to daily or twice-daily dosing.
Dalbavancin
Rifampicin
Meropenem
Imipenem
Amikacin
Doripenem
Imipenem/cilastatin/relebactam
Avibactam